Skip to main content
PMC home page
International Journal of Nanomedicine logoLink to International Journal of Nanomedicine
editorial
. 2013 Jan 9;8:201–202. doi: 10.2147/IJN.S41525

Personalized nanomedicine: future medicine for cancer treatment

Farooq A Shiekh 1,✉
PMCID: PMC3544349  PMID: 23326194

Cancer as a grave disease is becoming a larger health problem,1 and the medicines used as treatments have clear limitations.2–4 Chemotherapy, radiation, and surgery, all of which are drastic treatments, wreak havoc on healthy cells and tissues as well as cancerous ones.5–7 Pathophysiologically, there are more than 200 types of cancers,8,9 each with many variants.10 Some are aggressive, some are not; some are easily treated, and others are always fatal.11

Unlike previous “revolutions” in the “war” on cancer that raised hope, nanomedicine is not just one more tool, it is an entire field, and the science in this area is burgeoning, and benefiting from use of modern cutting edge molecular tools.12–14 These breakthrough advancements have radically changed the perception of future medicine. Importantly, they are enabling landmark research to combine all advances, creating nanosized particles that contain drugs targeting cell surface receptors and other potent molecules designed to kill cancerous cells.15–19 If there is a case to be made for personalized medicine, cancer is it. For example, the current literature reveals the need for a great scientific effort to be made in this field.20–22 However, new paradigms are needed to interpret toxicogenomic and nanotoxicological data in order to predict drug toxicities and gain a more indepth understanding of the mechanisms of toxicity, so that more specific therapeutic targets which are essentially devoid of side effects could be selected.23,24

The future of nanomedicine and the opportunity to eliminate the suffering and death due to cancer will hinge on our ability to confront cancer at its molecular level.25 Nevertheless, there are many outstanding questions that remain unanswered. A revolution in nanoscience is now heralding a long-awaited era of personalized cancer treatment that is now much closer than ever before. Personalized medicine will ensure that such drugs are given only to patients who stand to benefit from them. If that happens, nanobased drugs will be at least less toxic than today’s armamentarium for cancer. If they work as intended, they should also prove to be far more effective.

Footnotes

Disclosure

The author reports no conflicts of interest in this work.

References

  • 1.Parkin DM. International variation. Oncogene. 2004;23:6329–6340. doi: 10.1038/sj.onc.1207726. [DOI] [PubMed] [Google Scholar]
  • 2.Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010;328:1031–1035. doi: 10.1126/science.1183057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Colditz GA, Sellers TA, Trapido E. Epidemiology – identifying the causes and preventability of cancer? Nat Rev Cancer. 2006;6:75–83. doi: 10.1038/nrc1784. [DOI] [PubMed] [Google Scholar]
  • 4.Shiekh FA. Blood-brain barrier: a real obstacle for therapeutics. Int J Nanomedicine. 2012;7:4065–4066. doi: 10.2147/IJN.S33837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Horton JK, Wilson SH. Predicting enhanced cell killing through PARP inhibition. Mol Cancer Res. 2012 Nov 27; doi: 10.1158/1541-7786.MCR-12-0512. [Epub ahead of print.] [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Horton JK, Gleason JF, Jr, Klepin HD, Isom S, Fried DB, Geiger AM. Age-related disparities in the use of radiotherapy for treatment of localized soft tissue sarcoma. Cancer. 2011;117:4033–4040. doi: 10.1002/cncr.25996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Godat LN, Horton JK, Shen P, Stewart JH, Wentworth S, Levine EA. Recurrence after mastectomy for ductal carcinoma in situ. Am Surg. 2009;75:592–595. [PubMed] [Google Scholar]
  • 8.Service RF. Materials and biology. Nanotechnology takes aim at cancer. Science. 2005;310:1132–1134. doi: 10.1126/science.310.5751.1132. [DOI] [PubMed] [Google Scholar]
  • 9.Reed JC. Cancer. Priming cancer cells for death. Science. 2011;334:1075–1076. doi: 10.1126/science.1215568. [DOI] [PubMed] [Google Scholar]
  • 10.Ryan RJ, Bernstein BE. Molecular biology. Genetic events that shape the cancer epigenome. Science. 2012;336:1513–1514. doi: 10.1126/science.1223730. [DOI] [PubMed] [Google Scholar]
  • 11.Cao Y, DePinho RA, Ernst M, Vousden K. Cancer research: past, present and future. Nat Rev Cancer. 2011;11:749–754. doi: 10.1038/nrc3138. [DOI] [PubMed] [Google Scholar]
  • 12.Gewin V. Big opportunities in a small world. Nature. 2009;460:540–541. doi: 10.1038/nj7254-540a. [DOI] [PubMed] [Google Scholar]
  • 13.Hassan MH. Nanotechnology. Small things and big changes in the developing world. Science. 2005;309:65–66. doi: 10.1126/science.1111138. [DOI] [PubMed] [Google Scholar]
  • 14.Sukhanova A, Even-Desrumeaux K, Kisserli A, et al. Oriented conjugates of single-domain antibodies and quantum dots: toward a new generation of ultrasmall diagnostic nanoprobes. Nanomedicine. 2012;8:516–525. doi: 10.1016/j.nano.2011.07.007. [DOI] [PubMed] [Google Scholar]
  • 15.Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7:653–664. doi: 10.1038/nrclinonc.2010.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Prabhu P, Patravale V. The upcoming field of theranostic nanomedicine: an overview. J Biomed Nanotechnol. 2012;8:859–882. doi: 10.1166/jbn.2012.1459. [DOI] [PubMed] [Google Scholar]
  • 17.Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012;12:835–848. doi: 10.1038/nrc3397. [DOI] [PubMed] [Google Scholar]
  • 18.Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science. 2012;338:903–910. doi: 10.1126/science.1226338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kozako T, Arima N, Yoshimitsu M, Honda SI, Soeda S. Liposomes and nanotechnology in drug development: focus on oncotargets. Int J Nanomedicine. 2012;7:4943–4951. doi: 10.2147/IJN.S30726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Meyer UA. Personalized medicine: a personal view. Clin Pharmacol Ther. 2012;91:373–375. doi: 10.1038/clpt.2011.238. [DOI] [PubMed] [Google Scholar]
  • 21.Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011;17:297–303. doi: 10.1038/nm.2323. [DOI] [PubMed] [Google Scholar]
  • 22.Shute N. Personalized medicine. Sci Am. 2012;306:44. [PubMed] [Google Scholar]
  • 23.Sanhai WR, Sakamoto JH, Canady R, Ferrari M. Seven challenges for nanomedicine. Nat Nanotechnol. 2008;3:242–244. doi: 10.1038/nnano.2008.114. [DOI] [PubMed] [Google Scholar]
  • 24.Gershon D. Toxicogenomics gains impetus. Nature. 2002;415:4–5. doi: 10.1038/nj6869-04a. [DOI] [PubMed] [Google Scholar]
  • 25.William WN, Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov. 2009;8:213–225. doi: 10.1038/nrd2663. [DOI] [PubMed] [Google Scholar]

Articles from International Journal of Nanomedicine are provided here courtesy of Dove Press

RESOURCES